AYC-EVs injected into mouse models of asthma were found to reduce the levels of major factors (an increase in bronchoconstriction, Th2 cytokine levels, inflammatory cell infiltration, MUC5AC expression, eotaxin expression, IgE production, and lung inflammation), for developing asthma, and relieve pathological and immunological symptoms in animal models. This evidence concerns the gene IGHE and asthma.